MiRNAs in inflammatory skin diseases and their clinical implications

Expert Review of Clinical Immunology

Volumn 11, Issue 4, 2015, Pages 467-477

  Lovendorf, Marianne B ^a   Skov, Lone ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

allergic contact dermatitis; atopic dermatitis; biomarkers; miRNAs; non coding RNA; psoriasis

Indexed keywords

METHOTREXATE; MICRORNA; BIOLOGICAL MARKER;

ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; BIOGENESIS; DERMATITIS; DISEASE MARKER; GENE EXPRESSION; HUMAN; INNATE IMMUNITY; NONHUMAN; PSORIASIS; REVIEW; SKIN ALLERGY; ANIMAL; BIOLOGICAL THERAPY; DERMATITIS, ATOPIC; IMMUNOLOGY; METABOLISM; SKIN; TRENDS;

ADAPTIVE IMMUNITY; ANIMALS; BIOLOGICAL THERAPY; BIOMARKERS; DERMATITIS, ATOPIC; HUMANS; IMMUNITY, INNATE; MICRORNAS; PSORIASIS; SKIN;

EID: 84924952330     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1020301     Document Type: Review

References (94)

1. Ambros V, Lee RC, Lavanway A, et al. MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol 2003;13: 807-18
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
3. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136(2): 215-33
4. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54
5. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in caenorhabditis elegans. Nature 2000;403(6772):901-6
6. Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000;408(6808):86-9
7. miRBase. Available from: www.miRBase.org
8. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of miRNAs. Genome Res 2009;19: 92-105
9. Finnegan EF, Pasquinelli AE. MicroRNA biogenesis: regulating the regulators. Crit Rev Biochem Mol Biol 2013;48(1):51-68
10. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23: 4051-60
11. Lund E, Güttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004;303:95-8
12. Hutvanger G, Zamore PD. A microRNA in a multiple turnover RNAi enzyme complex. Science 2002;297:2056-60
13. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20
14. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011;12:99-110
15. Filipowicz W, Bhattacharyy SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 2008;9:102-14
16. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11(4):441-50
17. Baek D, Villeñ J, Shin C, et al. The impact of microRNAs on protein output. Nature 2008;455:64-71
18. Vlachos IS, Hatzigeorgiou AG. Online resources for miRNA analysis. Clin Biochem 2013;46:879-900
19. Poliseno L, Salmena L, Zhang J, et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010;465(7301):1033-8
20. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007;318:1931-4
21. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5 UTR as in the 3 UTR. Proc Natl Acad Sci USA 2007;104(23):9667-72
22. Kong YW, Ferland-McCollough D, Jackson TJ, et al. MicroRNAs in cancer management. Lancet Oncol 2012;13(6): e249-58
23. OConnell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNA in the immune system. Nat Rev Immunol 2010;10:111-22
24. Elmeñ J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452(7189):896-9
25. Lanford RE, Hildebrandt-Eriksen ES, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis c virus infection. Science 2010;327:198-201
26. Safety study of SPC3649 in healthy men. Available from: https://clinicaltrials.gov/ct2/show/NCT00688012
27. SPC3649 multiple dose study in healthy volunteers. Available from: https://clinicaltrials.gov/ct2/show/NCT00979927
28. Multiple ascending dose study of miravirsen in treatment-naïve chronic hepatitis c subjects. Available from: https://clinicaltrials. gov/ct2/show/NCT01200420
29. Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. J Cell Biol 2012;199(3):407-12
30. Van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014;6(7):851-64
31. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013;31:577
32. Andl T, Murchison EP, Liu F, et al. The miRNA-processing enzyme dicer is essential for the morphogenesis and maintenance of hair follicles. Curr Biol 2006;16:1041-9
33. Yi R, OCarroll D, Pasolli HA, et al. Morphogenesis in skin is governed by discrete sets of differentially expressed miRNAs. Nat Genet 2006;38:356-62
34. Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis?. PLoS One 2007;2(7):e610
35. Yi R, Poy MN, Stoffel M, et al. A skin microRNA promotes differentiation by repressing stemness. Nature 2008; 452(7184):225-9
36. Lena AM, Shalom-Feuerstein R, Rivetti di Val Cervo P, et al. miR-203 represses stemness by repressing DeltaNp63. Cell Death Differ 2008;15(7):1187-95
37. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014;32:227-55
38. Zibert JR, Løvendorf MB, Litman T, et al. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010;58(3): 177-85
39. Løvendorf MB, Zibert JR, Hagedorn PH, et al. Comparison of microRNA expression using different preservation methods of matched psoriatic skin samples. Exp Dermatol 2012;21:299-319
40. Joyce CE, Zhou X, Xia J, et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet 2011;20(20): 4025-40
41. Xia J, Joyce CE, Bowcock AM, et al. Noncanonical microRNAs and endogenous siRNAs in normal and psoriatic human skin. Hum Mol Genet 2013;22(4):737-48
42. Curtale G, Citarella F. Dynamic nature of noncoding RNA regulation of adaptive immune responses. Int J Mol Sci 2013;14: 17347-77
43. Lerman G, Avivi C, Mardoukh C, et al. MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One 2011;6(6):e20916
44. Xu N, Brodin P, Wei T, et al. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol 2011;131:1521-9
45. Xu N, Meisgen F, Butler LM, et al. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40. J Immunol 2013;190(2):678-88
46. Løvendorf MB, Mitsui H, Zibert JR, et al. Laser capture microdissection followed by next-generation sequencing identifies disease-related microRNAs in psoriatic lesions that reflect systemic microRNA changes in psoriasis. Exp Dermatol 2014. [Epub ahead of print
47. Rossi RL, Rossetti G, Wenandy L, et al. Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat Immunol 2011;12:796-803
48. Allantaz F, Cheng DT, Bergauer T, et al. Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression. PLoS One 2012;7:e29979
49. Mitsui H, Suárez-Fariñas M, Belkin DA, et al. Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. J Invest Dermatol 2012;132:1615-26
50. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204: 3183-94
51. Turner ML, Schnorfeil FM, Brocker T. MicroRNAs regulate dendritic cell differentiation and function. J Immunol 2011;187:3911-17
52. Wang S, Olson EN. AngiomiRs - key regulators of angiogenesis. Curr Opin Genet Dev 2009;19:205-11
53. Zhao M, Wang LT, Liang GP, et al. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol 2014;150(1):22-30
54. Løvendorf MB, Zibert JR, Gyldenløve M, et al. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. J Dermatol Sci 2014; 75(2):133-9
55. Lønnberg AS, Skov L, Skytthe A, et al. Heritability of psoriasis in a large twin sample. Br J Dermatol 2013;169(2):412-16
56. Tsoi LC, Spain SL, Knight J, et al. Identification of fifteen new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012;44(12): 1341-8
57. Wu LS, Li FF, Sun LD, et al. A miRNA-492 binding-site polymorphism in BSG (basigin) confers risk to psoriasis in central south Chinese population. Hum Genet 2011;130(6):749-59
58. Zhang W, Yi X, Guo S, et al. A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study. J Cell Mol Med 2014; 18(11):2225-34
59. Guttman-Yassky E, Dhingra N, Leung DYM. New era of biological therapeutics in atopic dermatitis. Expert Opin Biol Ther 2013;13(4):549-61
60. Sonkoly E, Janson P, Majuri ML, et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol 2010;126(3):581-9
61. Rebane A, Runnel T, Aab A, et al. MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. J Allergy Clin Immunol 2014; 134(4):836-47.e11
62. Vennegaard MT, Bonefeld CM, Hagedorn PH, et al. Allergic contact dermatitis induces upregulation of identical microRNAs in humans and mice. Contact Dermat 2012;67(5):298-305
63. Gulati N, Løvendorf MB, Zibert JR, et al. Unique miRNAs appear at different times during the course of a delayed-type hypersensitivity (DTH) reaction in human skin. Abstr. # 50 Annual meeting, Society Invest Dermatol (SID), Albuquerque, New Mexico, US; May 2014
64. Liu A, Tetzlaff MT, Vanbelle P, et al. MicroRNA Expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int. J Clin Exp Pathol 2009;2:519-27
65. Glud M, Klausen M, Gniadecki R, et al. MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J Invest Dermatol 2009;129:1219-24
66. Ralfkiaer U, Hagedorn PH, Bangsgaard N, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011;118(22):5891-900
67. Marstrand T, Ahler CB, Ralfkiaer U, et al. Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas. Leuk Lymphoma 2014;55(4):957-8
68. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006
69. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-18
70. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010;101:2087-92
71. Reid G, Kirschner MB, Zandwijk NV. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011;80:193-208
72. PubMed. Available from: www.PubMed.gov
73. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res 2012;5(3):492-7
74. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9(6):654-9
75. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009;2(100):ra81
76. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13(4):423-33
77. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108(12):5003-8
78. Oyama R, Jinnin M, Kakimoto A, et al. Circulating miRNA associated with TNF-a signaling pathway in Patients with plaque psoriasis. J Dermatol Sci 2011;61:206-17
79. Ichihara A, Jinnin M, Oyama R, et al. Increased serum levels of miR-1266 in patients with psoriasis Vulgaris. Eur J Dermatol 2012;22:68-71
80. Pivarcsi A, Meisgen F, Xu N, et al. Changes in the level of serum miRNAs in patients with psoriasis after antitumour necrosis factor-a therapy. British J Dermatol 2013;169:563-70
81. Garciá-Rodríguez S, Arias-Santiago S, Orgaz-Molina J, et al. Abnormal levels of expression of plasma microRNA-33 in patients with psoriasis. Actas Dermosifiliogr 2014;105(5):497-503
82. Guinea-Viniegra J, Jimeñez M, Schonthaler HB, et al. Targeting miR-21 to treat psoriasis. Sci Transl Med 2014;6(225): 225re1
83. Smith FJ, Hickerson RP, Sayers JM, et al. Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol 2008;128(1):50-8
84. Hickerson RP, Smith FJ, Reeves RE, et al. Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 2008;128(3):594-605
85. Leachman SA, Hickerson RP, Schwartz ME, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 2010;18(2):442-6
86. Yi X, Zhao G, Zhang H, et al. MITF-siRNA formulation is a safe and effective therapy for human melasma. Mol Ther 2011;19(2):362-71
87. Sonkoly E, Loveñ J, Xu N, et al. MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma. Oncogenesis 2012;1:e3
88. Sun V, Zhou WB, Majid S, et al. MicroRNA-mediated regulation of melanoma. Br J Dermatol 2014;171(2): 234-41
89. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006; 147(3):126-32
90. McDonald JS, Milosevic D, Reddi HV, et al. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011;57(6):833-40
91. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-77
92. Boele J, Persson H, Shin JW, et al. PAPD5-mediated 3 adenylation and subsequent degradation of miR-21 is disrupted in proliferative disease. Proc Natl Acad Sci USA 2014;111(31):11467-72
93. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature 2012;489:101-8
94. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012;22:1775-89